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In addition to the well known role of mast cells in immunity to multi-cellular parasites and
in the pathogenesis of allergy and asthma, the importance of mast cells in the immune
defense against bacteria and viruses is increasingly being recognized. Their location in the
skin, gut, and airways puts mast cells in an ideal location to encounter and respond to
pathogens, and in order to perform this function, these cells express a variety of pattern
recognition receptors, includingToll-like receptors (TLRs). Mast cells respond toTLR ligands
by secreting cytokines, chemokines, and lipid mediators, and some studies have found that
TLR ligands can also cause degranulation, although this ﬁnding is contentious. In addition,
stimulation viaTLR ligands can synergize with signaling via the FcεRI, potentially enhancing
the response of the cells to antigen in vivo. A great deal is now known aboutTLR signaling
pathways. Some features of these pathways are cell type-speciﬁc, however, and work is
under way to fully elucidate the TLR signaling cascades in the mast cell. Already, some
interesting differences have been identiﬁed. This review aims to address what is known
about the responses ofmast cells toTLR ligands and the signaling pathways involved. Given
the location of mast cells at sites exposed to the environment, the response of these cells
toTLR ligands must be carefully regulated. The known mechanisms behind this regulation
are also reviewed here.
Keywords: cytokine, innate, mast cells, review, signaling,TLRs
INTRODUCTION
Host cells utilize a variety of germline encoded receptors termed
pathogen recognition receptors (PRRs), including the Toll-like
receptors (TLR) and nucleotide-binding oligomerization domain
(NOD) proteins, to recognize pathogens. These receptors allow
the innate immune system to identify invading bacteria by their
expression of pathogen-associated molecular patterns (PAMPs;
Akira et al., 2006). Signaling via these receptors guides the immune
system to mount the correct response to an invading pathogen,
or to a harmless commensal, by a process which is not well
understood (Blander and Sander, 2012).
Mast cells have traditionally been known for their roles
in allergy and immunity to multi-cellular parasites (Metcalfe
et al., 1997) but increasingly the crucial roles that they play in
immune defense against bacteria and viruses are being recog-
nized (Marshall, 2004; Abraham and St John, 2010). Mast cells
are able to recognize pathogens via their expression of PRRs
and by binding to antibodies with the FcRs (Abraham and St
John, 2010). This review will focus on TLR expression, func-
tion and signaling, since the TLRs are the best studied PRR on
mast cells.
Abbreviations: AC, adenylate cyclase; BMMC, bone marrow-derived mast cell;
Btk, Bruton’s tyrosine kinase; CBMC, cord blood-derived mast cell; cysLT, cys-
teinyl leukotriene; FSDMC, fetal skin-derived mast cells; IFN, interferon; IGF-1,
insulin-like growth factor-1; IHC, immunohistochemistry; LBP, LPS-binding pro-
tein; MD-2, myeloid differentiation-2; n.d., not determined; P3C, tripalmitoyl
Cys-Ser-(Lys)4; PAMPs, pathogen-associated molecular patterns; PBDMC, periph-
eral blood-derived mast cell; PCDMC, peritoneal cell-derived mast cell; PI3K,
phosphoinositide 3-kinase; PKC, protein kinase C.
The TLRs are a family of receptors which recognize a wide
variety of PAMPs, as summarized in Table 1. Furthermore, it is
increasingly being recognized that certain endogenous molecules
which are expressed during tissue damage or disease are also
TLRs agonists (Kawai and Akira, 2010). There are 10 human
TLRs, TLR1–TLR10, while 13 are found in the murine genome,
TLR1–TLR9 and TLR11–TLR13 (Lee et al., 2012). The receptors
largely function as homodimers, with the exception of TLR2which
forms heterodimers with both TLR1 and TLR6 (Akira et al., 2006;
Lee et al., 2012). The TLR2 homodimers and heterodimers are
located on the cell surface, as are TLR4 and TLR5, while TLR3
and TLR7–TLR9 are endosomally located, allowing them to rec-
ognize intracellular nucleic acids (Lee et al., 2012). Among other
ligands, TLR4 recognizes LPS, TLR5 binds ﬂagellin, and TLR2
heterodimers recognize various lipopeptides (Akira et al., 2006;
Lee et al., 2012; Table 1).
Much work has been carried out to determine the signaling
pathways triggered by the TLR receptors and the consequences of
their ligation (Lu et al., 2008; Akira, 2009; Kawai and Akira, 2010).
This review aims to address the ability of mast cells to respond to
TLR ligands and to examine what is known about TLR signaling
and its regulation in mast cells. In addition, cross-talk between
the TLR signaling pathways and that of FcεRI has been identiﬁed
(Avila and Gonzalez-Espinosa, 2011), and the mechanisms and
consequences of this will be discussed.
TLR EXPRESSION ON MAST CELLS
Several studies have been undertaken on murine and human
mast cells isolated ex vivo, or differentiated from stem cells, as
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Table 1 |The mainTLR ligands (adapted fromAkira et al., 2006; Lee et al., 2012).
TLR Physiological ligands Synthetic ligands
TLR1–2 Triacylated lipopeptides (bacteria and mycobacteria) Pam3CSK4
TLR2 Peptidoglycan (gram positive bacteria), phospholipomannan (Candida albicans), tGPI-mucins
(Trypanosoma), haemagglutinin (measles virus), porins (Neisseria), lipoarabinomannan
(mycobacteria), glucuronoxylomannan (Cryptococcus neoformans), HMGB1 (host)
TLR2–6 Diacylated lipopeptides (Mycoplasma), LTA (Group B Streptococcus), zymosan
(Saccharomyces cerevisiae)
FSL1, MALP-2, Pam2CSK4
TLR3 dsRNA (viruses) PolyI:C
TLR4 LPS (Gram-negative bacteria), VSV glycoprotein G, RSV fusion protein, MMTV envelope
protein, mannan (Candida albicans), glucuronoxylomannan (Cryptococcus neoformans),
glycosylinositolphospholipids (Trypanosoma), HSP60, HSP70, ﬁbrinogen, HMGB1
(all host proteins), nickel
TLR5 Flagellin (Flagellated bacteria)
TLR7 ssRNA (RNA viruses) Imidazoquinoline compounds: imiquimod,
resiquimod, loxoribine, R848
TLR8 ssRNA(RNA viruses) Resiquimod
TLR9 CpG-DNA (bacteria and mycobacteria), DNA (viruses), haemozoin (Plasmodium) CpG-A, CpG-B and CpG-C ODNs
well as on mast cell lines to establish which TLRs are expressed.
The ﬁndings of these studies are summarized in Table 2. The
TLRs appear to be widely expressed by murine mast cells, with
expression of TLR1–4 and 6–9 identiﬁed at least at the mRNA
level (McCurdy et al., 2001; Supajatura et al., 2001; Masuda
et al., 2002; Ikeda and Funaba, 2003; Matsushima et al., 2004;
Li et al., 2009; Mrabet-Dahbi et al., 2009). Expression of TLR5
has not been demonstrated on murine mast cells (McCurdy
et al., 2001; Supajatura et al., 2001; Ikeda and Funaba, 2003;
Matsushima et al., 2004).
Expression of TLR1–10 with the exception of TLR8 has been
identiﬁed on human mast cells, although some studies were
unable to identify TLR1, 4, 6, or 9 (McCurdy et al., 2003; Oku-
mura et al., 2003; Varadaradjalou et al., 2003; Kulka et al., 2004;
Kulka and Metcalfe, 2006; Yoshioka et al., 2007). TLR expres-
sion on the mast cell lines LAD2, HMC-1, and MC-9 has been
assessed with varied results in different studies (McCurdy et al.,
2001; Masuda et al., 2002; Kulka et al., 2004; Kulka and Metcalfe,
2006; Kubo et al., 2007; Yoshioka et al., 2007). It should be noted
that several receptors have only been detected at the mRNA level
and that further work will be required to demonstrate protein
expression.
The expression of TLR2 by mast cells has been studied in
more detail and it has been suggested that bone marrow-derived
mast cell (BMMC) do not express the whole TLR2 protein
but rather a truncated protein lacking the intracellular signal-
ing domain (Mrabet-Dahbi et al., 2009). Despite this, a range of
studies have determined that mast cells are able to respond to
TLR2 ligands, as discussed below, and this may be due to the
fact that the truncated TLR2 is still able to form heterodimers
(Mrabet-Dahbi et al., 2009).
MAST CELL RESPONSES TO TLR STIMULATION
MAST CELL RESPONSES TO CELL SURFACE TLRs
Acting via TLR4, LPS caused IL-6, IL-13, and TNFα secretion
from murine BMMC (McCurdy et al., 2001; Supajatura et al.,
2001) and a later study found secretion of IL-5 and IL-10 upon
LPS stimulation via TLR4 (Masuda et al., 2002). In addition to
these cytokines, LPS stimulation of murine BMMC and fetal
skin-derived mast cells (FSDMC) also caused the secretion of the
chemokines CCL3/MIP-1α andCXCL2/MIP-2 (Matsushima et al.,
2004; Figure 1).
Differences between the cytokines produced upon TLR4 and
TLR2 stimulation have been observed: LPS causedmurine BMMC
to secrete TNFα, IL-6, IL-13, and IL-1β via TLR4; while peptido-
glycan (PGN) causes the secretion of TNFα and IL-6, in addition
to the Th2 cytokines, IL-4, IL-5, and IL-13 via TLR2 (Supajatura
et al., 2002; Figure 1). In rat peritoneal mast cells, both PGN and
LPS resulted in cysteinyl leukotriene production, but the response
to PGN was greater (Wierzbicki and Brzezinska-Blaszczyk, 2009).
Taken together, these ﬁndings suggest thatmast cells release awider
variety of mediators in response to PGN than LPS. This appears
not to be the case in macrophages, where stimulation with LPS
or PGN has been shown to lead to an up-regulation of similar
mRNAs (Wang et al., 2000).
Murine peritoneal cell-derivedmast cells (PCDMC) responded
more potently to TLR agonists than BMMC and it is suggested
that the PCDMCaremoremature than BMMC, and this increased
maturity underlines their increased ability to respond toTLR stim-
ulation (Mrabet-Dahbi et al., 2009). LTAandMALP-2 treatment of
PCDMC resulted in IL-1, IL-6, IL-17, GM-CSF, IL-10, TNFα, and
IFNγ production, while LPS caused only IL-6, GM-CSF, IL-10,
and TNFα secretion from PCDMC (Mrabet-Dahbi et al., 2009).
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Table 2 |TLR expression by mast cells.
Murine Human Cell line




+ PBDMC mRNA and protein3
+ CBDMC mRNA4
+ HMC-1 mRNA and protein3
− LAD2 mRNA and protein3,5
+ LAD2 protein5







+ PBDMC mRNA and protein3
+ CBDMC mRNA4
+ CBDMC mRNA and protein10
+ in polyps by IHC4
− HMC-1 mRNA and protein3,11
+ LAD2 mRNA and protein3,5,11
+ MC-9 mRNA7




+ PBDMC mRNA and protein3
+ Bone marrow3
+ LAD1 protein2
+ HMC-1 mRNA and protein3
+ LAD2 mRNA and protein3
TLR4 + BMMC mRNA1,6−9,12
+ BMMC protein1,9,13





+ PBDMC mRNA and protein3,14
+ CBDMC mRNA and protein10
− CBDMC mRNA4
+ MC-9 mRNA7,12
− HMC-1 mRNA and protein3
+ HMC-1 mRNA and protein11
+LAD2 mRNA and protein3,5,11




+ PBDMC mRNA and protein3
+ HMC-1 mRNA and protein3
+ LAD2 mRNA and protein3,5
− MC-9 mRNA7




+ PBDMC mRNA and protein3
+ CBDMC mRNA4
+ HMC-1 mRNA and protein3
+ LAD2 mRNA and protein3
+ MC-9 mRNA7




+ PBDMC mRNA and protein3
+ HMC-1 mRNA and protein3
+ LAD2 mRNA and protein3
TLR8 + BMMC mRNA8 − lung mRNA2
− skin mRNA2− PBDMC mRNA and protein3
+ HMC-1 mRNA and protein3
− LAD2 mRNA and protein3





+ PBDMC mRNA and protein3
+ HMC-1 mRNA and protein3
+ LAD2 mRNA and protein3,5
TLR10 No murine homolog + lung mRNA2
+ skin mRNA2
None tested
TLR expression on mast cells is summarized. The references are indicated by superscript numbers: 1Matsushima et al., 2004; 2Kulka and Metcalfe, 2006; 3Kulka
et al., 2004; 4McCurdy et al., 2003; 5Yoshioka et al., 2007; 6Ikeda and Funaba, 2003; 7McCurdy et al., 2001; 8Supajatura et al., 2001; 9Mrabet-Dahbi et al., 2009;
10Varadaradjalou et al., 2003; 11Kubo et al., 2007; 12Masuda et al., 2002.
Of these three agonists, only LTA-induced PGD2 production in
PCDMC (Mrabet-Dahbi et al., 2009; Figure 1).
In human cord blood-derived mast cells (CBMC), stimulation
with zymosan or PGN caused GM-CSF, IL-1β, LTB4, and LTC4
production (Olynych et al., 2006). Another study also identiﬁed
differences between themediators released upon different TLR lig-
and stimulation: PGN, zymosan, and Pam3Cys caused GM-CSF
and IL-1β secretion whereas LPS did not; and PGN and zymosan
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FIGURE 1 | Mast cell secretory responses toTLR ligation. A diagram
showing the molecules secreted by mast cells uponTLR ligation. The
cytokines, chemokines, and lipid mediators released uponTLR ligand
stimulation are summarized for murine BMMC, PCDMC, FSDMC, and
human mast cells. Where there is discrepancy in the literature, molecules are
shown in grey. *indicates instances where it has been demonstrated with the
use of TLR-deﬁcient cells or blocking antibodies that the ligand is acting via
the indicated receptor.
FIGURE 2 |TLR signaling in the mast cell. A scheme illustrating the
signaling pathways triggered byTLR ligation in the mast cell.Where there is
evidence in the literature for the involvement of a particular protein, the
protein is ﬁlled in black. Proposed molecules are in grey (adapted from
Akira et al., 2006; Lu et al., 2008; Park et al., 2009). The activation of PI3K
via c-kit or FcεRI stimulation is shown, with its inhibitory and activating
effects on MAPK activation.
treatment led to the productionof LTC4 unlike Pam3Cys treatment
(McCurdy et al., 2003). Human mast cells cultured from CD34+
progenitors isolated from blood (PBDMC) stimulated with LPS
produced signiﬁcant amounts of TNFα, whereas PGN induced
IL-1β, GM-CSF, IL-5, and cysteinyl leukotriene in addition to
TNFα (Kulka et al., 2004; Figure 1). Therefore, as has been shown
in murine mast cells, stimulation via TLR2 results in a greater
range of mediator production than stimulation via TLR4.
Pre-treatment of mast cells with cytokines has been shown
to enhance the response of the cells to TLR ligands (Okumura
et al., 2003; Varadaradjalou et al., 2003). In one study, LPS only
induced TNFα production after the CBMC had been incubated
with IL-4, whereas even untreated cells were able to respond to
PGN (Varadaradjalou et al., 2003). It is not clear why the cells in
this study were unable to respond to the TLR4 agonist without
TNFα pre-treatment (Varadaradjalou et al., 2003), unlike human
PBDMC (Kulka et al., 2004). Human lung mast cells and PBDMC
responded to LPS by secreting TNFα but this response, and TLR4
expression, was increased by pre-treatment with IFNγ (Okumura
et al., 2003). This group also noticed CCL1 and IL-5 production in
LPS-treated lung mast cells but not PBDMC, and gene array anal-
ysis showed that LPS caused the up-regulation of a variety of genes
including a protease, several cytokines, chemokines, receptors, and
STAT5a (Okumura et al., 2003).
Peptidoglycan has been demonstrated to induce migration
of peritoneal rat mast cells after a short treatment with TNFα
(Brzezinska-Blaszczyk and Rdzany, 2007), and in a later publi-
cation, LPS and PGN both caused migration of the cells after
treatment with IL-6 or CCL5/RANTES, respectively (Wierzbicki
and Brzezinska-Blaszczyk, 2009). The mechanism behind these
effects is as yet unknown, but it has been suggested that IL-6 and
CCL5/RANTES may modulate TLR expression on the mast cells
(Wierzbicki and Brzezinska-Blaszczyk, 2009). The ability of TLR
agonists to causemast cellmigration in vivowould allowPAMPs or
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endogenous TLR ligands produced upon tissue damage to recruit
mast cells to sites of infection or inﬂammation.
TLR5 expression has been more readily detected on human
thanmurine mast cells (see Table 1) and human PBDMC respond
to ﬂagellin (a TLR5 ligand) by secreting IL-1β and TNFα, demon-
strating that the receptor is functional on these cells (Kulka et al.,
2004; Figure 1). To our knowledge, ﬂagellin has not been shown
to cause cytokine secretion from murine mast cells, in agree-
ment with the lack of detectable expression of TLR5 on the cells
(McCurdy et al., 2001; Supajatura et al., 2001; Ikeda and Funaba,
2003; Matsushima et al., 2004).
MAST CELL RESPONSES TO INTRACELLULAR TLRs
Double-stranded RNA molecules, such as polyI:C, are used as a
synthetic mimic of viral RNA (see Table 1) and cause IFNα and β
secretion from human PBDMC and murine BMMC (Kulka et al.,
2004). This response was partially blocked with anti-TLR3 anti-
bodies and in TLR3−/− BMMC, suggesting that the receptor is
involved in the detection of the RNA (Kulka et al., 2004). A differ-
ent group found thatmurine FSDMCresponded farmore robustly
to polyI:C than BMMC, secreting IL-6, TNFα, CCL2/MIP-1α,
CXCL2/MIP-2, and CCL5/RANTES which was in agreement with
the greater TLR3 expression by FSDMCthanBMMC(Matsushima
et al., 2004). In a recent study using BMMC, no IL-6, TNFα or
IFNα/β production was observed upon polyI:C treatment (Keck
et al., 2011; Figure 1). The ability of BMMC to respond to TLR3
stimulation is, therefore, somewhat controversial, although mast
cells fromother sources clearly do respond (Kulka et al., 2004;Mat-
sushima et al., 2004). These ﬁndingmay reﬂect themore immature
phenotype of BMMC.
Murine BMMChave been found to respond to bacterial but not
mammalian DNA, and to synthetic oligonucleotides containing
an unmethylated cytosine followed by a guanosine (CpG motif),
by secreting IL-6 and TNFα (Zhu and Marshall, 2001). MC/9
cells were also found to respond to CpG-containing oligonu-
cleotides by secreting IL-6 and TNFα, and the response of
BMMC was greater when greater numbers of CpG sequences
were included in the oligonucleotides (Zhu and Marshall, 2001).
These treatments were not found to induce mast cell degranula-
tion or the secretion of GM-CSF, IL-4, IL-12, or IFNγ (Zhu and
Marshall, 2001). A later study comparing BMMC and FSDMC
found that TLR9 was expressed by FSDMC but not BMMC,
and demonstrated TNFα, IL-6, CCL2/MIP-1α, CXCL2/MIP-2,
and CCL5/RANTES secretion by FSDMC but not BMMC treated
with CpG-containing oligonucleotides (Matsushima et al., 2004;
Figure 1).
The TLR7 agonist, R848, caused secretion of IL-6 and TNFα
and also the chemokines CCL2/MIP-1α and CXCL2/MIP-2 from
FSDMC but not BMMC, and TLR7 expression was far higher in
FSDMC (Matsushima et al., 2004). In spite of this, R848 stim-
ulation of BMMC did lead to some CCL5/RANTES production
(Matsushima et al., 2004; Figure 1), therefore murine mast cells
appear to respond to TLR7 agonists, in agreement with their
expression of the receptor (see Table 2).
A study using human PBDMC found that CpG-containing
oligonucleotides stimulated cells to produce IFNα, IL-1β, TNFα,
and cysteinyl leukotriene (Kulka et al., 2004). CpG-containing
oligonucleotides activate TLR9 therefore these data suggest that
in addition to expressing TLR9 (see Table 2), both human
and murine mast cells are able to respond to TLR9 ligands by
secreting cytokines and lipid mediators. The sensitivity of mast
cells to TLR7 and TLR9 agonists would presumably assist in
the immune defense against bacteria, viruses, and Plasmodium
(see Table 1).
Fetal skin-derived mast cells express higher levels of TLR3,
TLR7, and TLR9 and respond more potently to agonists of these
receptors than BMMC (Matsushima et al., 2004), in a similarman-
ner to the greater response of FSDMC than BMMC to TLR2 and
4 agonists (Mrabet-Dahbi et al., 2009). These results are likely a
reﬂection of the immaturity of BMMC and suggest that responses
to some TLRs are better studied in mast cell models other than
BMMC (Matsushima et al., 2004; Mrabet-Dahbi et al., 2009).
Work performed in other immune cells has demonstrated that
TLR3 and 9 signaling requires endosomal acidiﬁcation and mat-
uration, presumably because these receptors are intracellularly
located (Ahmad-Nejad et al., 2002; Matsumoto et al., 2003; Akira,
2009). Similarly in FSDMC, the cytokine secretion induced by
polyI:C (TLR3 ligand), R848 (TLR7 ligand), and CpG (TLR9
ligand) was inhibited by an inhibitor of endosomal maturation
(Matsushima et al., 2004). In contrast, the mast cell response to
LPS was unaffected by the treatment (Matsushima et al., 2004), in
agreement with similar studies in a macrophage cell line (Ahmad-
Nejad et al., 2002), presumably because TLR4 binds LPS at the cell
surface.
THE EFFECT OF TLR LIGATION ON MAST CELL DEGRANULATION
AND PHENOTYPE
In addition to these ﬁndings that stimulation of mast cells with
TLR agonists leads to cytokine and chemokine production and
mast cell migration, some data suggest that mast cell degranu-
lation can be induced by TLR2 ligands. Stimulation of BMMC
with PGN resulted in mast cell degranulation whereas stimula-
tion via TLR4 did not (Supajatura et al., 2002). Similar results
were obtained in human mast cells (Varadaradjalou et al., 2003).
Stimulation of CBMC with PGN led to histamine release in
addition to cytokine release, whereas LPS stimulation caused
only cytokine secretion (Varadaradjalou et al., 2003). In another
study using human CBMC, the degranulation induced by PGN
was not found to be statistically signiﬁcant, while zymosan
and Pam3Cys induced signiﬁcant degranulation (McCurdy et al.,
2003). In vivo, i.d. injection of PGN but not LPS caused a
mast cell-dependent increase in vascular permeability, indicat-
ing that the TLR2 ligand was inducing mast cell degranulation
(Supajatura et al., 2002).
Other groups have been unable to demonstrate degranula-
tion after stimulation of mast cells with TLR ligands, however.
Neither LPS nor PGN induced degranulation of BMMC (Ikeda
and Funaba, 2003) or rat peritoneal mast cells (Wierzbicki and
Brzezinska-Blaszczyk, 2009), and studying BMMC and FSDMC,
Matsushima et al. (2004) did not detect degranulation in response
to LPS, PGN, polyI:C, R848, or CpG, suggesting that signaling
via TLR2–4, 7, and 9 does not cause mast cell degranulation.
In agreement with these ﬁndings, TLR1/TLR2, TLR2/TLR6, and
TLR4 agonists were not observed to cause degranulation of MC/9
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cells or BMMC in another study (Qiao et al., 2006). Degranula-
tion was not observed in BMMC or the more mature PCDMC
in response to the TLR2 ligands MALP-2, LTA, or PGN (Mrabet-
Dahbi et al., 2009).When these agonists were given i.p., no drop in
body temperature was observed, suggesting that TLR2 activation
does not lead to degranulation of mast cells in vivo (Mrabet-Dahbi
et al., 2009).
It is difﬁcult to reconcile the differences in the ﬁndings of these
various studies. It may be that differences in the cell culture or
isolation methods, or differences in the agonist preparations used
could explain the discrepancies.
In other settings, TLR ligands have inhibited mast cell degran-
ulation. Stimulation of LAD1 cells with dsRNA analogues resulted
in decreased adhesion of the cells to ﬁbronectin and vitronectin
via TLR3, which led to a decrease in the degranulation observed
when cells were allowed to adhere to these proteins (Kulka and
Metcalfe, 2006). LTA and PGN acted over 24–48 h to downregu-
late surface levels of FcεRI expression on LAD2 cells and human
lung mast cells, which resulted in a decreased degranulation after
antigen exposure (Yoshioka et al., 2007). The effect was only par-
tially mediated by TLR2 and was not observed with TLR4, 5, or 9
agonists (Yoshioka et al., 2007).
These ﬁndings suggest that TLR signalingmay affect the pheno-
type ofmast cells, for example by downregulating FcεRI expression
(Yoshioka et al., 2007). Human mast cells cultured in vitro in
the presence of LPS or PGN had altered protease composition
and cytokine production proﬁles (Kirshenbaum et al., 2008). In
another study, LPS has been shown to cause an increase in
TLR4 expression in LAD2 cells, such that increased levels of
TNFα were produced after a second stimulation with LPS (Kubo
et al., 2007). This is in contrast to work performed on BMMC
where classical endotoxin-tolerance was observed and cells were
unresponsive to a second LPS challenge (Sly et al., 2004; Saturnino
et al., 2010).
In conclusion, the ability of TLR2 agonists to cause mast cell
degranulation is controversial and further work is required to clar-
ify the situation. It seems that TLR stimulation affects themast cell
phenotypemodulating the levels of receptors and proteases. Expo-
sure of mast cells to TLR agonists in vivo, therefore, may control
their ability to respond to other stimuli and the type of response
they are able to mount.
TLR SIGNALING IN THE MAST CELL
LACK OF TRIF-DEPENDENT PATHWAY IN TLR4 SIGNALING
IN THE MAST CELL
Theprototypical TLR4 ligand is LPSwhich is boundby the secreted
protein, LPS-binding protein (LBP) and transferred to the TLR4
signaling complex by cell secreted ormembrane boundCD14 (Lee
et al., 2012). TLR4 acts in a complex with MD-2 (Lee et al., 2012)
and this has also been shown to be the case in mast cells (Ushio
et al., 2004). It is now recognized that CD14 is only required for
the cell to recognize rough LPS but not smooth LPS (which con-
tains full-length O-chains; Jiang et al., 2005; Huber et al., 2006;
Lee et al., 2012).
Conventionally, TLR4 signaling proceeds via two signal-
ing pathways: the MyD88-dependent and the TRIF-dependent
(MyD88-independent) pathways (Lu et al., 2008; Akira, 2009;
Kawai and Akira, 2010). Activation of the MyD88-dependent
pathway leads to the production of pro-inﬂammatory cytokines
via activation of AP-1, IRF-5, and NF-κB. This pathway requires
the adaptor protein, TIRAP, to mediate the interaction between
TLR4 and MyD88. The adaptor TRAM is required for TLR4 to
activate the TRIF pathway which leads to the activation of IRF-3
and, therefore, interferon-β (IFNβ) production. This pathway also
causes a delayed NF-κB activation which contributes to the pro-
duction of pro-inﬂammatory cytokines (Lu et al., 2008; Akira,
2009; Kawai and Akira, 2010).
In BMMC, it appears that TLR4 signaling proceeds only via the
MyD88-dependent pathway and that the TRIF-dependent path-
way is not used (Keck et al., 2011). LPS stimulation of mast
cells does not lead to IFN production (Dietrich et al., 2010; Keck
et al., 2011) and TRIF deﬁciency does not affect the BMMC
cytokine secretion induced by LPS (Keck et al., 2011). In addition,
LPS-induced NF-κB activation is entirely dependent on MyD88
(Figure 2; Keck et al., 2011).
BMMC were observed to express reduced levels of TRAM, the
adaptor protein that links TRIF to the TLR4 receptor complex
(Keck et al., 2011). This reduction in TRAM may prevent TLR4,
and therefore LPS, from activating the TRIF pathway (Keck et al.,
2011). It does not appear to fully account for the defect, however,
as although TRAM over-expressing BMMC produced increased
IL-6 upon LPS stimulation, IFN production was still not detected
(Keck et al., 2011).
TLR4 signaling via theMyD88-dependent pathway occurs from
the cell membrane, whereas TRIF-mediated signaling is believed
to occur in early endosomes after internalization of the TLR4 com-
plex (Kagan et al., 2008). TLR4 is not internalized after stimulation
on mast cells (Dietrich et al., 2010; Keck et al., 2011), and while in
macrophages LPS is transported inside the cell, this is not the case
in mast cells (Dietrich et al., 2010). It seems likely that this lack
of internalization may explain why the TRIF-dependent pathway
does not occur in mast cells. CD14 is required for the internaliza-
tion of TLR4 (Zanoni et al., 2011; Lee et al., 2012) and although
BMMC express CD14 mRNA (Ikeda and Funaba, 2003), they do
not express detectable levels of CD14 on the cell surface, andCD14
must be provided in serum for the response to LPS (McCurdy et al.,
2001; Varadaradjalou et al., 2003). Therefore, this lack of CD14
may explain why TLR4 is not efﬁciently internalized in mast cells
and, therefore, why the TRIF pathway is not activated by LPS
(Keck et al., 2011).
The lack of CD14 on the cell surface may not fully explain
the inability of LPS to stimulate the TRIF pathway in mast cells,
however, since IFNα/β production (albeit reduced) is observed
upon LPS stimulation of CD14−/− macrophages suggesting
that CD14-independent TRIF activation is possible (Keck et al.,
2011). It is not clear whether this is due to a limited degree of
CD14-independent internalization of TLR4 or if the TRIF path-
way is activated from the plasma membrane in this condition
(Keck et al., 2011).
The inability of LPS to stimulate the TRIF-dependent pathway
is not unique to mast cells. Neutrophils stimulated with LPS simi-
larly produce no IFN (Tamassia et al., 2007). It has been suggested
that the lack of TRIF signaling in response to LPS may be a pro-
tective mechanism to prevent excessive activation of mast cells by
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the commensal bacteria routinely encountered by the cells due to
their location at sites close to the interface with the environment
(Keck et al., 2011). The same may be true for other cell types and
it is not known how many other cells respond in this way to TLR4
stimulation (Tamassia et al., 2007).
In addition to its key role in TLR4 signaling, CD14 is known
to be involved in the responses of other TLRs to various lig-
ands, although the molecular details are not fully understood (Lee
et al., 2012). Therefore, the lack of surface CD14 may affect the
response of mast cells to TLR2 and TLR5 ligands. Since CD14
mRNA has been detected in mast cells (Ikeda and Funaba, 2003) it
is possible that the protein is available intracellularly and may
be involved with TLR3 and TLR7–9 signaling. Further stud-
ies will be required to determine CD14 intracellular expression
in mast cells and what function this protein may play in TLR
signaling.
Further extending these ﬁndings that LPS treatment does not
cause IFNα/β secretion, Keck et al. (2011) demonstrated that nei-
ther infection with an adenoviral vector nor B-DNA transfection,
both of which stimulate macrophages to produce IFNβ, caused
IFN production in mast cells. Gene array analysis of human cells
found that whilst a group of interferon response genes were upreg-
ulated by LPS in monocytes, this upregulation did not occur in
mast cells (Okumura et al., 2003). The lack of type I IFN produc-
tion upon LPS stimulation of human mast cells was conﬁrmed
by quantitative PCR, suggesting that the IFN response to LPS is
lacking in humanmast cells as it is inmurinemast cells (Okumura
et al., 2003; Keck et al., 2011).
Mast cells are not entirely defective in IFNproduction, however.
Infection with vesicular stomatitis virus caused IFN production
(Keck et al., 2011), and polyI:C treated human and murine mast
cells secrete IFNα and β (Kulka et al., 2004) although this ﬁnding
was not reproduced in a later study (Keck et al., 2011). It seems
that the ability of mast cells to mount a potent IFN response is
tightly regulated.
ACTIVATION OF IRAKs
The family of interleukin-1 receptor-associated kinases (IRAKs)
are involved in the downstream signaling of TLRs (Akira, 2009;
Kawai and Akira, 2010). Very little is known about their roles
in TLR signaling in mast cells. In MC-9 cells, LPS and P3C were
shown to activate IRAK1 in an in vitro kinase assay, suggesting that
this kinase is important in signaling from TLR4 and TLR2/TLR1
(Figure 2; Qiao et al., 2006). Future studies are needed to address
the roles played by IRAK1 other members of this family in TLR
signal transduction in the mast cell.
MAPK ACTIVATION BY TLR LIGANDS IN MAST CELLS
The MAPKs are known to play a key role in TLR signaling in
immune cells (Akira,2009; Kawai andAkira,2010) and their role in
TLR signaling in themast cell has been addressed in several studies.
The involvement of p38, Erk, and Jnk in mast cell TLR signaling
has been demonstrated, although there are some discrepancies
between studies. There seems to be more support for a role of p38
and Jnk in the TLR signaling pathways in the mast cell than for
Erk, although some studies have identiﬁed Erk as an important
player.
TLR4, TLR2/1, and TLR2/6 signaling activated p38 MAPK in
BMMC in a comparable manner to stimulation through FcεRI
(Zorn et al., 2009). Furthermore, an inhibitor of p38 reduced the
IL-6 produced upon stimulation with LPS, Pam3CSK4, or FSL-1,
suggesting that this kinase plays a role in TLR2 and 4 signaling
(Zorn et al., 2009). Interestingly, inhibition of p38 phosphoryla-
tion caused a reduction in the secretion of IL-13 and IL-10 from
BMMC upon LPS stimulation but did not reduce the mRNAs of
these cytokines, suggesting that p38 regulates the production of
these cytokines post-transcriptionally (Masuda et al., 2002).
In addition to p38 phosphorylation, Masuda et al. (2002)
detected Jnk1/2 and p38 activation after LPS stimulation of MC-
9 cells and BMMC which was similar to that induced by FcεRI
signaling, together with a weaker Erk1/2 phosphorylation. In
contrast, in a separate study, Jnk1/2 phosphorylation was not
detected in BMMC after LPS stimulation (Supajatura et al., 2001).
It has been suggested that this discrepancy may be explained by
the sensitivity of the assays used, since Jnk1/2 activation was
demonstrated in an in vitro kinase assay in the later study while
Jnk-phosphorylation was undetectable by western blot (Masuda
et al., 2002). A more recent study on BMMC revealed phospho-
rylation of p38, Jnk1/2, and Erk1/2 after LPS stimulation but no
Erk5 phosphorylation which was induced by stimulation of FcεRI
(Li et al., 2009).
Inhibition of Jnk with curcumin reduced the amount of IL-10
and IL-13 but not IL-5 produced by BMMC and MC/9 cells upon
LPS stimulation, and similar results were obtained after over-
expression of a dominant negative Jnk in MC/9 cells (Masuda
et al., 2002). Production of the anti-microbial peptide, CRAMP
upon LPS stimulation of BMMCwas not dependent on theMAPK
p38, Jnk1/2, or Erk (Li et al., 2009).
The IFNα production induced upon polyI:C stimulation of
human PBDMC was inhibited by pharmacological inhibitors of
Jnk and p38, suggesting that these pathways are also involved in
TLR3 signaling in mast cells (Kulka et al., 2004). In support of
these ﬁndings, Jnk and p38 phosphorylation was observed after
stimulation of human PBDMC with polyI:C (Kulka et al., 2004).
Treatment of LAD2 cells with LPS, LTA,PGN,ﬂagellin, or CpG-
containing oligonucleotides resulted in phosphorylation of Erk
(Yoshioka et al., 2007). In MC/9 cells, however, neither LPS nor
the TLR2/TLR1 ligand, P3C was observed to cause Erk phos-
phorylation while both ligands induced detectable Jnk and p38
phosphorylation (Qiao et al., 2006). Speciﬁc inhibitors of all three
MAPKs reduced the TNFα production induced by the ligands,
suggesting that Erk does play a role in the TLR signaling in
MC/9 cells, even though Erk phosphorylation was not detected
(Qiao et al., 2006). In a separate study, however, pharmacologi-
cal inhibition of Erk phosphorylation had no effect on the IL-5,
-10, or -13 secretion induced by LPS in either MC/9 or BMMC
(Masuda et al., 2002).
Pam3CSK4 induced Erk-phosphorylation in BMMC that was
dependent on TLR2 and MyD88, and an inhibitor of MEK, the
MAPK upstream of Erk, reduced the LTC4 and PGD2 produc-
tion induced by Pam3CSK4, conﬁrming the importance of Erk
in this signaling pathway in mast cells (Kikawada et al., 2007).
SustainedErk phosphorylationwas not observed inmast cells deﬁ-
cient for the group V secretory PLA2, and as a result the amount
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of leukotriene and prostaglandin produced upon stimulation of
these cells with Pam3CSK4 was reduced (Figure 2; Kikawada et al.,
2007). The crucial role of the PLA2 on signaling seems to be spe-
ciﬁc to the TLR2 pathway as the deﬁcient mast cells responded as
wild-type cells to SCFand to stimulation throughFcεRI (Kikawada
et al., 2007).
In conclusion, it seems that p38, Jnk, and Erk are all involved in
TLR signaling in themast cell, and that their relative predominance
depends on the cells and stimuli type and concentration used, as
well as the particular cytokine of interest.
REQUIREMENT FOR ADENYLATE CYCLASE
It has been demonstrated in epithelial cells that the IL-6 pro-
duction observed upon TLR4 stimulation is dependent upon the
secondary messenger cAMP activating the transcription factor
CREB (Song et al., 2007). Similarly in mast cells, inhibition of
adenylate cyclase (AC) in CBMC reduced the IL-6 production in
response to PGN and Pam3CSK4, but had no effect on the IL-1β
produced (Haidl et al., 2011; Figure 2). This ﬁnding suggests that
cAMP is important in themast cells response to TLR2 stimulation,
although interestingly, it may be redundant in the production of
IL-1β (Haidl et al., 2011).
CALCIUM SIGNALING AND PROTEIN KINASE ACTIVATION IN TLR
SIGNALING IN THE MAST CELL
Calcium is not thought to be involved in TLR signaling path-
ways (Lu et al., 2008; Akira, 2009; Kawai and Akira, 2010), but is
an important secondary messenger in the FcεRI signaling path-
way in the mast cell which leads to degranulation (Gilﬁllan and
Tkaczyk, 2006). Since some studies have demonstrated that TLR
ligands cause mast cell degranulation (Supajatura et al., 2002;
McCurdy et al., 2003; Varadaradjalou et al., 2003), while others
have been unable to reproduce these ﬁndings (Ikeda and Funaba,
2003; Matsushima et al., 2004; Qiao et al., 2006; Mrabet-Dahbi
et al., 2009; Wierzbicki and Brzezinska-Blaszczyk, 2009), it is per-
haps not surprising that similar discrepancies exist in the literature
describing the ability of TLR agonists to cause calcium release in
mast cells.
In MC-9 cells and BMMC, LPS, PGN, MALP-2, and P3C were
unable to induce calcium signaling (Qiao et al., 2006). In contrast,
it has been shown inBMMCthatPGNcauses calciummobilization
which was dependent on TLR2, but LPS did not have this effect
(Supajatura et al., 2002). As discussed, the discrepancies between
these two studies are difﬁcult to reconcile.
Protein kinase C (PKC) α and β appear to have no role
in LPS signaling in the mast cell, since BMMC deﬁcient in
either kinase responded as well as wild-type cells to LPS, and an
inhibitor of PKCs had only minimal effects on the response (Zorn
et al., 2009).
Similarly, PKCs do not appear to play an important role in
TLR2 signaling in the mast cell, since an inhibitor of PKC did
not reduce the levels of CCL2/MCP-1 produced upon Pam3CKS4
stimulation of BMMC (Murphy et al., 2007). PKD1, however, was
shown to be activated in BMMC upon treatment with the TLR2
agonist, Pam3CKS4 (Figure 2; Murphy et al., 2007). The phospho-
rylation of PKD1 was dependent on MyD88 and reduced levels of
CCL2/MCP-1 mRNA and protein were produced by cells when a
PKD inhibitor was added, suggesting that the kinase is important
in the response of the cells to TLR2 ligands (Murphy et al., 2007).
A more recent study in macrophages also identiﬁed a crucial role
for PKD1 in Myd88-dependent TLR signal transduction (Park
et al., 2009). Further work will be required to understand the
roles of PKD1 and other protein kinases in TLR signaling in the
mast cell.
ROLE OF BTK IN MAST CELL TLR SIGNALING
Bruton’s tyrosine kinase (Btk) interacts with several TLR receptors
and components of the TLR signaling pathway including IRAK1
and TIRAP, and the kinase is activated by LPS in THP-1 cells
(Jefferies et al., 2003). The role this kinase plays in TLR signaling
is controversial. In one study, mononuclear cells from patients
with mutations in Btk showed an impaired TNFα response to
LPS, demonstrating that this kinase is required for TLR4 signal-
ing (Horwood et al., 2003). Whereas, another study on monocytes
from patients deﬁcient in Btk found no such defect in TLR4 sig-
naling (Perez de Diego et al., 2006). Murine Btk−/− macrophages
produced reduced levels of IL-10 in response to several TLR ago-
nists than wild-type cells, which resulted in an increase in the
amount of IL-6 produced (Schmidt et al., 2006).
Btk is important in signaling through the FcεRI (Gilﬁllan
and Tkaczyk, 2006), demonstrating that the tyrosine kinase is
expressed and functional in mast cells. Btk does not appear to
play a vital role in TLR signaling in the cells, however, since the
response to TLR4, TLR2/TLR1, andTLR2/TLR6 ligandswas either
unaffected or enhanced in BTK-deﬁcient mast cells (Zorn et al.,
2009). Phosphorylation of p38 upon LPS stimulation was unaf-
fected by Btk deﬁciency in BMMC (Zorn et al., 2009). These data
suggest that the kinase may have an inhibitory role in TLR signal-
ing in the mast cell, in contrast to that which has been described
in monocytes and macrophages (Horwood et al., 2003; Schmidt
et al., 2006; Zorn et al., 2009).
ACTIVATION OF TRANSCRIPTION FACTORS
Roles for several transcription factors have been demonstrated
in TLR activation, including AP-1-binding proteins (such as c-
jun and c-fos) and NF-κB (Akira, 2009; Kawai and Akira, 2010)
and some of these have been implicated in TLR signaling in the
mast cell.
In BMMC, LPS and PGN caused phosphorylation of IκB-α at
Ser32 (Supajatura et al., 2002) which would lead to NF-κB acti-
vation. In an earlier publication, it was demonstrated that IκB-α
phosphorylation after LPS stimulation only occurred inC3H/HeN
BMMC and not in BMMC derived from the C3H/HeN TLR4-
mutated strain, demonstrating that this activation was induced
via TLR4 (Supajatura et al., 2001), and this was supported by the
lack of IκB-α phosphorylation after LPS stimulation of TLR4−/−
BMMC (Supajatura et al., 2002). Similarly, IκB-α phosphoryla-
tion was not observed in TLR2−/− BMMC after PGN stimulation
(Supajatura et al., 2002).
A more recent study detected limited IκBα degradation upon
LPS stimulation and greater levels of IκBβ degradation, partic-
ularly at time points of over an hour, conﬁrming that NFκB
signaling occurs upon TLR4 signaling inmast cells (Li et al., 2009).
Inhibition of this pathway reduced the levels of transcription of
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an anti-microbial peptide, demonstrating the importance of this
pathway in the response (Li et al., 2009).
NF-κB signaling is also implicated in TLR signaling in human
mast cells. IκB phosphorylation was detected in human PBDMC
after polyI:C stimulation, and the IFNα induced upon polyI:C
treatment of the cells was inhibited with a chemical inhibitor of
NF-κB (Kulka et al., 2004). In humanCBMC,PGNandPam3CSK4
induced IL-6 and IL-1β production was inhibited by an inhibitor
of IκK-2, suggesting that the NF-κB pathway is also important
in TLR2 signaling in human mast cells (Haidl et al., 2011). In
agreement with these ﬁndings that NF-κB is activated upon TLR2
and TLR4 stimulation of mast cells, NF-κB-binding activity was
detected in nuclear extracts of MC/9 cells after stimulation with
LPS and P3C (Qiao et al., 2006).
Taken together, these studies clearly deﬁne an important role
for NF-κB in TLR2 and TLR4 signal transduction in human
and murine mast cells (Figure 2). P3C and LPS treatment of
MC/9 cells resulted in phosphorylation of ATF-2 and, to a lesser
extent, c-Jun implying that these two transcription factors are
involved in the signal transduction pathways of TLR2 and 4 in
mast cells (Figure 2; Qiao et al., 2006). In the same study, c-
fos activity was not induced by either ligand, nor was STAT 3,
5, or 6 activation detected (Qiao et al., 2006). Further work will
be required to determine whether these transcription factors are
activated in human and murine mast cells in addition to this
cell line.
As discussed above, in stark contrast to the situation in
macrophages, LPS stimulation of mast cells does not lead to IFN
production (Dietrich et al., 2010; Keck et al., 2011). This is reﬂected
in the activation of the transcription factor IRF-3 (Keck et al.,
2011). In macrophages, LPS treatment causes IRF-3 phosphoryla-
tion which is not observed in BMMC, even when soluble CD14 is
added to the media. When LPS is administered i.p., IRF-3 phos-
phorylation was observed by ﬂow cytometry in macrophages but
not mast cells, demonstrating that this difference between the two
cell types also exists in vivo (Keck et al., 2011).
EFFECT OF PI3K SIGNALING
Phosphoinositide 3-kinase (PI3K) is composed of a p110 catalytic
subunit and a p85 regulatory subunit and its action produces
lipid mediators which act as secondary messengers and activate
downstream kinases. The PI3K pathway is a regulator of TLR
signaling which can have either positive or negative effects on
signaling depending on cell type and stimulus, as reviewed by
Hazeki et al. (2007).
Since PI3K activation leads to phosphorylation of the kinase
AKT, AKT phosphorylation can be used as a readout for PI3K
activation. AKT phosphorylation was not detected after LPS or
P3C activation of MC/9 cells, suggesting that these TLR4 and
TLR2 ligands do not activate the PI3K pathway in these cells
(Qiao et al., 2006).
Inhibition of the PI3K pathway with two pharmacological
inhibitors reduced the amount of TNFα, IL-6, and IL-1β pro-
duced by BMMC upon LPS stimulation (Sly et al., 2004). In
a more recent study, however, whilst Wortmannin reduced the
amount of TNFα and IL-6 produced while the IL-1β production
was increased, suggesting that the pathway differentially regulates
cytokine production in mast cells (Hochdorfer et al., 2011). These
disparate ﬁndings regarding the role of PI3K signaling in IL-
1β production are difﬁcult to reconcile, particularly since both
studies used BMMC and similar concentrations of Wortmannin
(Sly et al., 2004; Hochdorfer et al., 2011). Co-treatment of cells
withLPS andknownPI3K stimulating factors such as IGF-1 caused
an increase in the amount of TNFα produced, but inhibited the
production of IL-1β in murine BMMC and PCDMC (Hochdorfer
et al., 2011; Figure 2).
The differential effects of PI3K activation on TNFα and IL-1β
is intriguing, and a similar result was obtained in human mono-
cytes, in that the inhibition of PI3K differentially affected the
production of two cytokines (Martin et al., 2003). When mono-
cytes were stimulated with LPS in the presence of PI3K inhibitors,
the amount of IL-12 produced was increased whilst the amount
of IL-10 produced was inhibited (Martin et al., 2003). The mech-
anism behind the disparity appears to be that inhibition of PI3K
led to suppression of Erk1/2 activation, and Erk has been previ-
ously demonstrated to cause the production of IL-10 and suppress
IL-12 production in RAW264.7 cells (Yi et al., 2002). Perhaps a
similar mechanism is at work in mast cells, and may explain
the opposing effect that PI3K activation has on TNFα and IL-1β
production.
Activation of the SCF receptor, c-kit, potently induces PI3K
signaling in mast cells, and there are several mutations of the c-
kit receptor which are associated with human disease that result
in constitutive c-kit activation (Robyn and Metcalfe, 2006). This
raised the interesting possibility that mast cells in patients with
particular c-kit mutations may respond differently to stimula-
tion with LPS. Indeed, the L138.8A mast cell line which contains
such a c-kit activating mutation did not produce IL-1β upon
LPS stimulation unless PI3K signaling was chemically inhibited
(Hochdorfer et al., 2011). It is interesting to speculate that mast
cell responses to TLR agonists in vivo may be modulated by other
stimuli that the cell encounters that activate the PI3K signaling
pathway.
ACTIVATION OF INHIBITORY PATHWAYS
Several pathways that inhibit TLR signaling have been identiﬁed
which presumably act to prevent over-reaction of cells to TLR
ligands which could result in immune-mediated pathology (Kawai
and Akira, 2010). The presence of some of these pathways has
been investigated in mast cells, and several have been shown to be
functional in the cells.
In macrophages, TIRAP becomes phosphorylated and
degraded by SOCS1 after TLR2 and TLR4 activation, which con-
sequently prevents further signaling via the MyD88-dependent
pathway (Mansell et al., 2006). This inhibitory pathway does not
occur in mast cells, however, and the levels of TIRAP remain
unchanged after stimulation (Zorn et al., 2009). In mast cells, LPS
activation leads to a reduction in the levels of mRNA of SOCS1
and CISH (a SOCS family member), whereas in macrophages it
results in an increase in the levels of SOCS1, SOCS3, and CISH,
which are thought to be responsible for the degradation of TIRAP
(Mansell et al., 2006; Zorn et al., 2009).
The SH2-containing inositol phosphatase (SHIP) inhibits
the NF-κB pathway during FcεRI stimulation of mast cells
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(Kalesnikoff et al., 2002) and has been shown to be upregu-
lated in both mast cells and macrophages after LPS stimulation
(Sly et al., 2004). The ability of SHIP to negatively regulate
TLR4 signaling is illustrated by the demonstration that injection
of a sub-lethal concentration of LPS was lethal in SHIP deﬁ-
cient animals (Sly et al., 2004). SHIP inhibits signaling through
the PI3K pathway (Huber et al., 1998) and since inhibition of
PI3K inhibits the LPS-induced cytokine production in mast cells
(Sly et al., 2004; Hochdorfer et al., 2011), it seems logical that
SHIP would inhibit TLR4 signaling in these cells. Indeed, SHIP-
mediated negative feedback has been shown to be important in
the phenomenon of endotoxin-tolerance in both mast cells and
macrophages, since endotoxin-tolerance could not be induced
in SHIP−/− mast cells or macrophages (Sly et al., 2004). The
SHIP expression in LPS stimulated mast cells and macrophages is
caused by autocrine TGFβ, implying that this regulatory cytokine
is important in inhibiting the response to LPS in both cell types
(Sly et al., 2004).
As previously discussed, inhibition of the PI3K pathway inmast
cells does not inhibit all cytokine production stimulated by LPS.
Rather, the production of IL-1β was enhanced when the path-
way was inhibited (Hochdorfer et al., 2011). In support of this,
whilst LPS stimulation of SHIP−/− mast cells resulted in greater
TNFα production, the amount of IL-1β secreted was reduced
(Hochdorfer et al., 2011).
DAP12 is a transmembrane protein which has been shown to
inhibit the response of macrophages to TLR agonists (Hamerman
et al., 2005). DAP12−/− BMMC, however responded to TLR4,
TLR2/TLR1, and TLR2/TLR6 agonists in a comparable manner
to wild-type cells, suggesting that the signaling pathways in mast
cells are independent of DAP12 (Smrz et al., 2010).
TANK is a negative regulator of TLR signaling (Kawagoe et al.,
2009) and has been identiﬁed in gene array analysis as being up-
regulated in LPS stimulated mast cells (Okumura et al., 2003),
raising the possibility that itmay be involved in a negative feedback
loop. Further work will be required to determine whether this
protein indeed inhibits TLR signaling, and to establish what other
pathways are important in the regulation of TLR-mediated mast
cell activation.
Other as yet unidentiﬁed mechanisms may be in place to limit
the response of the mast cell to LPS, or perhaps, since this does
not result in IFN production (Dietrich et al., 2010; Keck et al.,
2011), regulation of the mast cell LPS response is less crucial
than that of macrophages. Indeed, it has been suggested that
the lack of TRIF signaling in response to LPS may be a protec-
tive mechanism to prevent excessive activation of mast cells by
the commensal bacteria routinely encountered by the cells due to
their location at sites close to the interface with the environment
(Keck et al., 2011).
RECEPTOR CROSS-TALK BETWEEN TLRs AND OTHER
RECEPTORS ON MAST CELLS
Dectin-1 is a PPR which is known to interact with several TLRs,
and behaves as a co-receptor for TLR2 (Gantner et al., 2003; Reid
et al., 2009). Dectin-1 is believed to be primarily expressed on
myeloid cells, and has been shown to be expressed on human
mast cells (Olynych et al., 2006). Inhibition of dectin-1 reduced
the LTC4 produced upon CBMC stimulation with zymosan but
not PGN, and did not inhibit the production of GM-CSF or
IL-1β (Olynych et al., 2006). These data suggest that the PPR
is involved in mast cell recognition of zymosan, presumably in
conjunction with TLR2, but not of PGN, and that the receptor
is required for cell signaling to induce the production of lipid
mediators but not cytokines (Olynych et al., 2006). In support
of this, pharmacological inhibition of the tyrosine kinase Syk,
which is activated by dectin-1, inhibited the production of LTC4
induced by zymosan and to a lesser extent by PGN. Syk is therefore
important in the downstream signaling from TLR2 in mast cells
(Olynych et al., 2006).
Stimulation of mast cells via TLRs results in cytokine and
chemokine production in a similar way to that observed for other
cells (Akira et al., 2006; Kawai and Akira, 2010). Mast cells are
unique in that they express the FcεRI in addition to TLRs, and so
there is the potential for cross-talk between these two cell stim-
ulatory pathways. Several studies have addressed the impact of
TLR signaling on stimulation of mast cells via the FcεRI and
vice versa.
Mast cells sensitized with IgE respond more robustly to LPS
stimulation (Medina-Tamayo et al., 2011). This enhanced sensi-
tivity is not due to an increase in the expression of TLR4, CD14,
or MD-2, rather the cells appear to be “pre-activated” by binding
IgE and show higher basal levels of NF-κB activation (Medina-
Tamayo et al., 2011). This ﬁnding adds to earlier demonstrations
that IgE binding to the FcεRI activates mast cells to some extent
(Kawakami and Kitaura, 2005). In addition, the anti-apoptotic
effect of monomeric IgE on mast cells is synergistically enhanced
by the addition of LPS, signaling via TLR4, although LPS alone
had no effect on apoptosis (Jayawardana et al., 2008).
In addition to these effects, the FcεRI signaling pathway shares
many features with TLR signaling, for example both pathways
utilize MyD88 (Gilﬁllan and Tkaczyk, 2006; Akira, 2009; Kawai
andAkira, 2010), therefore there is potential for cross-talk between
the two pathways (Avila and Gonzalez-Espinosa, 2011).
The cytokine production of BMMC andMC/9 cells upon stim-
ulation via the FcεRI receptor is synergistically enhanced in the
presence of the TLR4 agonist, LPS, and the TLR2/TLR1 ago-
nist P3C, and to a lesser extent by that of MALP-2 and PGN
(both TLR2/TLR6 agonists; Qiao et al., 2006). In contrast, the
degranulation response is unaffected (Qiao et al., 2006).
Stimulation of BMMC with the TLR2 ligands MALP-2 and
Pam3CSK4 synergizes with stimulation through FcεRI to enhance
IL-6 production (Fehrenbach et al., 2007). MALP-2 had no effect
on FcεRI-induced degranulation whereas Pam3CSK4 inhibited
antigen-induced degranulation, although this was found to be
due to a direct interaction between the model antigen and the
lipid itself, rather than any cross-talk between signaling pathways
(Fehrenbach et al., 2007).
Signaling through FcεRI induces PI3K activation in mast cells
(Yano et al., 1993; Gilﬁllan and Tkaczyk, 2006) and, as previously
discussed, inhibition of the PI3K pathway during LPS stimulation
results in an inhibition of IL-6 and TNFα (although the effect
on IL-1β production is contentious), suggesting that this pathway
acts to increase responses to LPS (Sly et al., 2004; Hochdorfer et al.,
2011; Figure 2). In agreement with this, stimulation of BMMC via
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FcεRI enhances the IL-6 andTNF inducedbyLPS,whilst inhibiting
the IL-1β production (Hochdorfer et al., 2011).
In MC/9 cells, synergy has also been observed between TLR4
and FcεRI induced Jnk and p38, but not Erk phosphorylation
(Masuda et al., 2002; Qiao et al., 2006). The use of selective MAPK
inhibitors, however, did suggest a role for Erk signaling in the syn-
ergy between the two signaling pathways (Qiao et al., 2006). In
contrast, Smrz et al. (2010) found no evidence of synergy between
FcεRI and TLR signaling in the activation of p38, Erk, or Jnk. The
activation of the transcription factors, ATF-2, c-Jun, and c-Fos
upon stimulation via FcεRI was increased in the presence of either
TLR2 or TLR4 stimulation (Qiao et al., 2006).
Synergy was not observed for the calcium response induced by
antigen, indeed, P3C was shown to inhibit the calcium release
induced by mast cell activation via the FcεRI pathway by an
unknown mechanism (Qiao et al., 2006). Similarly, the IRAK1
activation caused by the TLR ligands was slightly inhibited by
antigen stimulation (Qiao et al., 2006).
Synergy between TLR and FcεRI signaling pathways therefore
has been demonstrated (Qiao et al., 2006; Figure 2), and results
in enhanced cytokine secretion but not degranulation (Qiao et al.,
2006; Fehrenbach et al., 2007; Hochdorfer et al., 2011). Much of
this work has been performed inmurinemast cells and it would be
interesting to investigate the phenomenon in the human context.
It has been proposed that the increased response to stimulation via
FcεRI in the presence of TLR2 and 4 ligands may contribute to the
worsening of allergic symptoms which can occur in the presence
of pathogens (Qiao et al., 2006).
CONCLUSION
Recent research identiﬁes important roles for mast cells in the
immune defense against bacteria and pathogens (Marshall, 2004;
Abraham and St John, 2010) and given their locations at sites of
microbial entry into the host (Metcalfe et al., 1997) the ability of
the cells to recognize invading pathogens must be crucial. A vari-
ety of PRRs are responsible for initial recognition of pathogens
(Akira et al., 2006) and of these, the TLRs are the best studied in
mast cells.
Mast cells have been shown to express the majority of TLRs
(Table 2) and respond to their agonists by secreting cytokines,
chemokines and lipid mediators which would have a profound
effect on other cells of the immune system. In addition, TLR
ligation can act to enhance the response of mast cells to anti-
gen, sensitizing the cells to stimulation through FcεRI (Qiao et al.,
2006; Fehrenbach et al., 2007; Hochdorfer et al., 2011). To date,
the majority of the work investigating the function of TLRs has
been performed in vitro with only a few studies in vivo (Supa-
jatura et al., 2002; Mrabet-Dahbi et al., 2009). Further studies are
therefore required to fully elucidate the role of TLR signaling in
mast cells.
The signal transduction pathways triggered by TLR stimulation
of mast cells are beginning to be elucidated and have some unique
features. Strikingly, the MyD88-independent pathway which leads
to IFN production is not induced by TLR4 activation, which may
be due to a lack of cell surface CD14 (Keck et al., 2011). Indeed, the
ability of mast cells to secrete IFN in response to other TLR stim-
ulation is somewhat controversial (Kulka et al., 2004; Keck et al.,
2011). In addition, some of the inhibitory pathways which have
been identiﬁed in other immune cells are not observed to occur in
mast cells (Hamerman et al., 2005; Zorn et al., 2009).
As described, several discrepancies are noted in the literature
reporting the signaling pathways utilized by TLRs in mast cells
and the response to TLR agonists. Notably, the ability of TLR2
ligation to induce degranulation is contentious, as is the abil-
ity of mast cells to respond to TLR3 ligation and the relative
importance of the different MAPK proteins in TLR signal trans-
duction. These differences may be explained by different mast
cell culture conditions resulting in heterogeneous cell popula-
tions possibly with different expression of TLRs and signaling
proteins. Further work is needed to consolidate the data. Given
the importance of mast cells in the immune defense to bacte-
ria and viruses (Marshall, 2004; Abraham and St John, 2010),
it is important that the signal transduction pathways utilized by
TLRs and the consequences of TLR signaling in these cells are
understood.
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